Erteberel - Eli Lilly and Company
Alternative Names: LY 500307; SERBA-1Latest Information Update: 28 Nov 2021
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Indiana University; National Institute of Mental Health
- Class Antipsychotics; Benzopyrans; Mood stabilisers; Small molecules
- Mechanism of Action Estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mood disorders
- Discontinued Benign prostatic hyperplasia; Schizophrenia
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for clinical-Phase-Unknown development in Mood disorders in USA
- 08 Sep 2021 Discontinued - Phase-II for Schizophrenia in USA (PO)
- 04 Oct 2018 Clinical trials in Mood disorders in USA (unspecified route) (NCT03689543)